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INTRODUCTION
Diabetes is a multifactorial disease, in which 2 major factors,
namely insulin resistance and impaired insulin secretion, or a com-
bination thereof, contribute to the onset or deterioration of the
disease. Glycemic control is often difficult to achieve, and when
patients with diabetes have comorbid diseases or conditions, the
glycemic profiles may become even more complicated and make
the treatment more difficult. However, if we can gain an understand-
ing of the pathophysiological causes and typical glycemic profiles
of patients with diabetes and certain comorbid diseases and condi-
tions, we may be able to predict the possible glycemic profiles and
establish tailor -made treatments for individual cases. Empirically
and theoretically, the typical glycemic profiles associated with many
of these conditions have been determined ; however, these find-
ings were acquired mainly from finger-prick blood glucose levels
at various time intervals, and what actually happens during a 24-h
span is still somewhat obscure.
Continuous glucose monitoring system (CGMS) can be used to
measure the interstitial glucose concentration, which closely ap-
proximates the plasma glucose after a short time lag. CGMS pro-
vide detailed information regarding the 24-h glycemic profiles,
including nocturnal and postprandial glycemia, which standard
finger-prick blood glucose monitoring regimens cannot provide us
(1-5). Therefore, the use of CGMS has the potential to provide
more informative and precise insights into the glycemic profiles of
type 2 diabetes patients with various comorbid diseases or con-
ditions, such as steroid use, liver cirrhosis, or enteral feeding. In
order to verify and provide information about the substantial gly-
cemic profiles associated with these conditions, we are presenting
examples of results obtained with 2 kinds of CGMS devices (Med-
tronic MiniMed, CGMS-GOLD and iPro2, Northridge, CA, USA)
(6) in patients with the 3 above-mentioned conditions, together
with the actual treatments for the individual cases. Furthermore, we
also present a case with late dumping syndrome for which CGMS
clearly demonstrated the virtual glucose profile and effectiveness
of the treatment.
STEROID-INDUCED HYPERGLYCEMIA
Glucocorticoids, such as prednisolone, are commonly used to
treat a wide variety of both acute and chronic illnesses, and remain
a valuable and necessary component of the therapy for many dis-
eases. However, the use of glucocorticoids may be accompanied
by multiple side effects, including hyperglycemia, and can result in
worsening of preexisting diabetes or in the induction of de novo
“steroid- induced” diabetes (7, 8). In fact, glucocorticoids are the
most common cause of drug- induced diabetes (7), and the inci-
dence rate of diabetes secondary to the use of glucocorticoids has
been reported to range between 2-50% (9-15). The odds ratio for
new-onset diabetes mellitus in patients treated with glucocorticoids
ranges from approximately 1.5 -2.5 (15, 16), and the total glucocor-
ticoid dose and duration of therapy have been demonstrated to be
strong predictors of diabetes induction, along with age and body
mass index (15, 16).
Mechanisms for steroid-induced hyperglycemia development
The mechanisms by which glucocorticoids cause diabetes pre-
dominantly involve insulin resistance rather than decreased insulin
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production (7, 15, 16), however, a reduction in insulin secretory
capacity has been observed at higher doses of corticosteroid use
(17). Glucocorticoids decrease the liver’s sensitivity to insulin,
thereby increasing the hepatic glucose output (15, 18). They more-
over inhibit glucose uptake in muscle and fat, thus reducing insulin
sensitivity. These observations are thought to be primarily due to
a postreceptor effect, or in other words, either due to inhibition
of glucose transport or decreased glycogen synthesis (19-25). In
addition to these factors, counterregulatory hormones, such as glu-
cagon, have been demonstrated to be augmented by glucocorticoid
administration (26).
Management for steroid-induced hyperglycemia
Oral glucocorticoids are often administered in the morning to
mimic the diurnal rhythm of cortisol (7), and the peak effect occurs
approximately 4 to 6 hours after dosing (7, 27). Therefore, the
glucose levels generally start to rise mid-morning or early after-
noon and continue to increase until bedtime (7, 27), which is char-
acterized by the development of postprandial hyperglycemia (7, 12).
Accordingly, glucose- lowering therapy should be predominantly
directed at the time of after lunch and/or dinner.
As for the treatment of steroid- induced hyperglycemia, the cur-
rently available agents used in the treatment of type 2 diabetes
mellitus, including sulfonylureas, metformin, thiazolidinediones,
and insulin have been suggested as potential treatment options for
non-critically ill patients (15, 28). While oral agents are available
for mild hyperglycemia, marked hyperglycemia, especially in
diabetic patients or patients with liver or renal disease, requires
insulin. The dose of insulin can be adjusted depending on the
glucose levels, and special caution will be necessary when the dose
of glucocorticoid is tapered or discontinued because, although the
effects of glucocorticoids on hyperglycemia usually remit within
48 hours of discontinuation of oral drug administration (28), the glu-
cose levels may drop dramatically after that, which may consequently
lead to an increased risk of hypoglycemia.
Case reports
Case 1 : A 51-year-old female patient with a 7-year history of
diabetes. Her glycated hemoglobin (HbA1c) level was 6.2% with
medication of metformin (750 mg/day) and the dipeptidyl pepti-
dase-4 inhibitor (DPP-4 inhibitor) sitagliptin (100 mg/day). She
was diagnosed with autoimmune hepatitis and was consequently
admitted to our hospital where oral administration of glucocorti-
coids 30 mg/day once a day in the morning was initiated. Seven
days after drug initiation, the dose was tapered to 25 mg/day. The
dosage of metformin and sitagliptin had been maintained throughout
the admission period. The results of the CGMS showed postpran-
dial hyperglycemia after lunch and dinner ; however, because the
levels of hyperglycemia were relatively mild and the escalation was
attenuated when glucocorticoid administration was tapered from
30 mg/day (Fig. 1a) to 25 mg/day (Fig. 1b), insulin therapy was
not required in this patient.
Case 2 : A 76-year-old female patient with a 4-year history of
diabetes. Her HbA1c level was 7.9% with medication of glimepiride
(0.5 mg/day), miglitol (225 mg/day), and alogliptin (12.5 mg/
day). She received 20 mg of dexamethasone once a week in the
morning as a part of her treatment for multiple myeloma, and she
required short -acting human insulin injections (NovolinR) 3 times
a day before every meal on the day of and the day after dexametha-
sone administration to control steroid- induced hyperglycemia. On
the day of dexamethasone administration (Fig. 2b), even with the
insulin injections, the CGMS results showed postprandial hyper-
glycemia mainly in the afternoon, which was not seen the day be-
fore drug administration (Fig. 2a). Her postprandial hyperglycemia
remained to the next day, even after insulin injections (Fig. 2c) ;
however, one day later, it was attenuated without insulin injection
(Fig. 2d). This case is a good example of how the effects of glu-
cocorticoids on hyperglycemia may persist to the next day after
Fig. 1 Results of the continuous glucose monitoring system (CGMS iPro2) in case 1.
The patient received glucocorticoids (30 mg/day) (a), which were subsequently tapered to 25 mg/day (b).
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discontinuation of the drug.
Case 3 : A 71-year-old male patient with a 6-year history of dia-
betes. His HbA1c level was 7.3%, and he was receiving metformin
(1,000 mg/day) and miglitol (1,000 mg/day). One month prior, he
was diagnosed with rheumatic polymyalgia, and prednisolone (15
mg/day, administered in the morning) was initiated for treatment.
Soon after treatment initiation, the patient was admitted to our hos-
pital, and glycemic control with insulin and a DPP-4 inhibitor, alo-
gliptin (25 mg/day), was initiated. Initially, short -acting human
insulin (NovolinR) was used before breakfast and lunch, and
long-acting insulin, glargine (Lantus), was used before bedtime.
During the admission period, because his postprandial hypergly-
cemia was significant (Fig. 3a ; day 1), short -acting insulin was
changed to a rapid-acting insulin, aspart (NovoRapid), and the
doses of insulin were increased. Glargine was also switched to the
long-acting degludec (Tresiba) with changes of dose and timing
of injection. These changes attenuated postprandial hyperglycemia
after breakfast and lunch, although postprandial hyperglycemia
after dinner still remained (Fig. 3b ; day 11). After the doses of
insulin administered before lunch and dinner were increased,
postprandial hyperglycemia after dinner was also attenuated
(Fig. 3c ; day 12).
DIABETES MELLITUS IN LIVER CIRRHOSIS
Patients with liver cirrhosis (LC) often show glucose intolerance.
Among LC patients, the incidence of glucose intolerance and de-
fined diabetes has been reported to be 60-80% and 10-60%, respec-
tively (29-34). Diabetes developed secondary to cirrhosis is known
as “hepatogeneous diabetes” (HD), and HD is clinically distinct
from type 2 diabetes ; it is less frequently associated with positive
family history, and the risk of diabetic complication (e.g., macro
and microangiopathy) is low (31, 32, 35).
Pathogenesis of diabetes mellitus in cirrhosis
Insulin resistance in muscular, hepatic, and adipose tissues, as
well as hyperinsulinemia, seem to be pathophysiologic bases for
Fig. 2 Results of the continuous glucose monitoring system (CGMS-GOLD) in case 2.
(a) The day before dexamethasone administration. (b) The day of drug administration. (c) Day 2 after drug administration. (d) Day 3 after drug
administration. R indicates short -acting human insulin (NovolinR), and the numbers in parentheses indicate the doses of insulin injections
administered before breakfast, lunch, dinner, and sleep, respectively. The arrow in (b) indicates the time of dexamethasone administration.
Fig. 3 Results of the continuous glucose monitoring system (CGMS-GOLD) in case 3.
(a) Day 1, (b) day 11, and (c) day 12 of monitoring, R indicates short -acting human insulin (NovolinR). Gla indicates long acting insulin glargine
(Lantus). Asp indicates rapid-acting insulin aspart (NovoRapid). Deg indicates long-acting insulin degludec (Tresiba). The numbers in pa-
rentheses indicate the doses of insulin injections administered before breakfast, lunch, dinner, and sleep, respectively.
The Journal of Medical Investigation Vol. 62 February 2015 3
HD (32, 36-38). Peripheral insulin resistance in HD is reportedly
explained by decreased glucose transport and by a defect in insulin-
stimulated nonoxidative glucose disposal (glycogen synthesis)
(29, 31, 37, 39-41). Peripheral insulin resistance may also occur at
the receptor or postreceptor level on target cells (42, 43). Hyper-
insulinemia observed in LC patients may be explained as an attempt
to overcome insulin resistance (40, 44, 45), diminished hepatic
extraction (34, 36, 42), and portocaval/intrahepatic shunting (45-
48). In cases of β -cell decompensation, diabetes worsens (33).
Management of diabetes mellitus in cirrhosis
In general, patients with liver disease and standard type 2 dia-
betes can be treated similarly. However, oral diabetic medications
should be used cautiously and may even be contraindicated in pa-
tients with decompensated liver failure with ascites or encepha-
lopathy, since these patients are expected to have altered drug
metabolism (36, 49). For example, metformin and thiazolenediones
have been shown to be effective in improving liver transaminases,
in addition to histological improvement in steatosis and inflamma-
tion ; however, metformin is not recommended for patients with
advanced hepatic disease, given the risk of lactic acidosis (36, 49).
Although some LC patients exhibit fasting hypoglycemia, they also
have postprandial hyperglycemia (37), and therefore the manage-
ment of HD may be targeted to control postprandial hyperglycemia
and avoid hypoglycemia. Short half - life sulfonylureas (rapid-acting
insulin secretagogues) and α -glucosidase inhibitors (α -GIs) can
be used for this purpose (31, 49-51).
Insulin treatment is frequently required in patients with diabetes
and LC, and insulin requirements may vary between individuals,
depending on to reduced gluconeogenesis and decreased hepatic
breakdown of insulin (36). On the other hand, some patients may
have an increased need for insulin because of insulin resistance.
To control postprandial hyperglycemia and to reduce the risk of
hypoglycemia, rapid-acting insulin should be considered (36, 49).
A late evening snack is beneficial to improve the catabolic state
during starvation and to avoid hypoglycemia in early morning
fasting (52-55).
Case reports
Case 4 : A 74-year-old female patient with a 13-year history of
diabetes and LC caused by idiopathic portal hypertension (IPH).
The exact timing of onset of IPH was not clear. Her HbA1c level
was 7.5%, with insulin injections of rapid-acting and long-acting
insulin, together with the α -GI, miglitol (150 mg/day). After admis-
sion, doses of rapid-acting insulin, glulisine (Apidra), immediately
before each meal, and long-acting insulin, glargine, before break-
fast, were adjusted. A Rapid-acting insulin secretagogue, repaglinide,
was added to miglitol administration, and this was administered
immediately before each meal (3 mg/day). During the admission
period, even with the aforementioned medications, the patient
showed postprandial hyperglycemia (Fig. 4a and 4c), which was
not seen when she skipped her breakfast because of an abdominal
ultrasound examination (Fig. 4b). In this case, glargine was used,
since she showed both insulin resistance and decreased insulin
secretion (24 h collected urinary C-peptide : 13.9 μg/day). Glargine
was administered before breakfast, rather than before bedtime,
to avoid hypoglycemia during the night and early morning.
Case 5 : A 52-year-old male patient suffered from LC, progressed
from hepatitis C. His diabetes developed 3 years prior. Repaglinide
was initiated, and since it was not able to control his glycemic
profiles (HbA1c 7.2%), insulin injections were administered. Since
the patient habitually consumed 2 meals a day (brunch and dinner),
an altered schedule of glulisine (6 units before brunch and 4 units
before dinner) and miglitol (50 mg immediately before each meal)
was used to control his postprandial hyperglycemia. On the day
when he had brunch and dinner, even with medication, postpran-
dial hyperglycemia was seen after each meal (Fig. 5a). On the day
when he had 3 meals, postprandial hyperglycemia was also seen
after every meal (Fig. 5b). CGMS results showed hypoglycemia
occurred during the night (Fig. 5a and 5b), and therefore a late
evening snack may be effective for this patient.
Fig. 4 Results of the continuous glucose monitoring system (CGMS-GOLD) in case 4.
(a) Day 1, (b) day 2, and (c) day 3 of monitoring. Glu indicates rapid-acting insulin glulisine (Apidra). Gla indicates long acting insulin glargine
(Lantus). The numbers in parentheses indicate the dose of insulin injections administered immediately before breakfast, immediately before
lunch, immediately before dinner, and before sleep, respectively. The arrow in (b) indicates the time that the patient skipped her breakfast and
insulin injection because of an abdominal ultrasound examination.
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HYPERGLYCEMIA IN PATIENTS RECEIVING EN-
TERAL NUTRITION
Patients receiving continuous enteral feeding are at high risk of
developing hyperglycemia (56-58). The prevalence of hypergly-
cemia as a complication of enteral nutrition therapy has been re-
ported to be as high as 35% of hospitalized adult patients (59) and
50% of elderly patients in long-term care (60). Since extensive
evidence indicates that the hyperglycemia during parenteral and
enteral nutrition is associated with increased risk of infection and
death (57), efforts should be made to maintain appropriate glyce-
mic control during enteral feeding.
Management of hyperglycemia during enteral nutrition
To lower blood glucose levels in case of hyperglycemia, adjust-
ment of the carbohydrate content of the enteral formula, or use of
pharmacotherapy, is necessary (56, 57, 61). Compared with stan-
dard high carbohydrate formulas, lower carbohydrate enteral for-
mulas, such as diabetes-specific formulas, have been shown to
reduce hyperglycemia, improve HbA1c levels, and lower insulin
requirements (57, 62-66). In standard formulas, carbohydrates
account for 55-60% of the total calories, while in diabetes-specific
formulas (low total carbohydrates, high fiber, and high monoun-
saturated fatty acid), carbohydrates account for only 35-40% of the
total calories (61, 64, 65).
Regarding pharmacotherapy, sulfonylureas should be used with
caution, in order to avoid hypoglycemia, especially during tube feed
interruptions (61). Alpha-GIs, glinides, and DPP-4 inhibitors may
provide a measure of glycemic control, but they are less efficacious
than rapid-acting insulin (61). In patients with moderate to severe
hyperglycemia, insulin injections are necessary, and administration
of long-acting insulin in combination with supplemental short -
acting insulin is effective in improving glycemic control (58). The
combination of long- and short -acting insulin has also been shown
to be superior to the sliding scale insulin strategy in patients re-
ceiving enteral feedings (57).
Several studies have also recommend alternative insulin regimens,
including the administration of regular insulin (every 4-6 h), NPH
insulin (every 8-12 h), insulin glargine or detemir (once-or twice
daily), and 70/30 biphasic insulin (two or three times daily) (61,
67-70). In all regimens, frequent and cautious reassessment of
patients’ clinical status is important for maintaining adequate gly-
cemic control and preventing hypoglycemia (57).
Case reports
Case 6 : An 85-year-old male patient was admitted to our hos-
pital because of dysphagia and aspiration pneumonia. The pneumo-
nia resolved but dysphagia persisted ; therefore, percutaneous en-
doscopic gastrostomy (PEG) was performed and enteral nutrition
therapy initiated. The patient received 200 ml of standard formula
(Terumeal 2.0α, Terumo Tokyo, Japan), and 200 ml of tepid water
in the morning around 8 AM, and again in the evening around 5-
6 PM. The patient also received 300 ml of Terumeal 2.0α and 100
ml of tepid water at noon. Terumeal 2.0α contains 7.25 g proteins,
7.5 g lipids, and 26 g of carbohydrates per 100 ml. Each enteral
feeding was performed slowly, lasting approximately 2 hours, in
order to avoid diarrhea and vomiting. Before admission, the patient
had been taking a DPP-4 inhibitor, sitagliptin (100 mg/day) and
HbA1c was 7.1% at the time of admission. During admission, sita-
gliptin (50 mg/day) was administered once in the morning during
feeding (around 8 AM), and the patient showed fair glycemic
control, without severe hyperglycemia or hypoglycemia (Fig. 6a
and 6b).
Case 7 : A 65-year-old male patient with brain hemorrhage was
rushed to our hospital after losing consciousness. After craniotomy
to remove a hematoma, PEG was performed and enteral nutrition
Fig. 5 Results of the continuous glucose monitoring system (CGMS iPro2) in case 5.
(a) On the day when the patinet had brunch and dinner, (b) On the day when the patient had 3 meals. Glu indicates rapid-acting insulin glulisine
(Apidra). The numbers in parentheses indicate the dose of insulin injections administered immediately before brunch or breakfast and imme-
diately before dinner, respectively. The arrows in (a) indicate the time of his meal (brunch and dinner) and insulin injections. On the day when he
consumed 3 meals (b), the arrows indicate the times of his meals with insulin injections only (breakfast and dinner).
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therapy was initiated. Since the patient exhibited hyperglycemia and
elevated HbA1c (7.4%), a diabetes-specific formula (Glucerna -Ex,
Abbot Japan, Tokyo, Japan) was used for enteral feeding. The for-
mula contains 4.2 g proteins, 5.6 g of lipids, 8 g carbohydrates, and
1.4 g of dietary fiber per 100 ml. The patient received 500 ml (500
kcal) of Glucerna -Ex three times a day, starting at approximately
6 AM, 12 AM, and 5 PM, with each feeding lasting approximately
2 hours. Between feedimgs, 300 ml of tepid water was also admin-
istered to avoid dehydration. The patient required insulin injections
of NovolinR at the time of each enteral feeding, and since the
patient exhibited hyperglycemia reaching 300 mg/dl, even with
4-10 units of insulin (Fig. 7a and 7b), we were forced to adjust
insulin dosage thereafter.
Fig. 6 Results of the continuous glucose monitoring system (CGMS iPro2) in case 6.
(a) Day 1 and (b) day 2 of monitoring. EN indicates enteral nutrition. The brackets indicate the duration of enteral feeding (approximately 2 hours).
Fig. 7 Results of the continuous glucose monitoring system (CGMS iPro2) in case 7.
(a) Day 1 and (b) day 2 of monitoring. EN indicates enteral nutrition. The brackets indicate the duration of enteral feeding (approximately 2 hours).
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REACTIVE HYPOGLYCEMIA DUE TO LATE DUMP-
ING SYNDROME
Reactive hypoglycemia can be caused by late dumping syndrome
in patients who have undergone esophageal or gastric surgery
(71-74), with moderate- to-severe dumping reported in approxi-
mately 10-40% of cases after gastrectomy (71, 74). The symptoms
of dumping syndrome-associated hypoglycemia include sweating,
fatigue, disturbed consciousness, tremor, and tachycardia ; these
normally occur 1-3 h after a meal (71, 74). The fast delivery of
food to the small intestine causes rapid glucose absorption and a
rapid rise in the blood glucose levels, which lead to exaggerated
secretion of glucagon- like peptide-1 and insulin, and, in turn,
causes reactive hypoglycemia (71, 75-77).
Treatment for late dumping syndrome
Most patients with dumping syndrome can be treated by diet
and lifestyle modification (71, 74, 78). To prevent rapid delivery of
large amounts of glucose from food to the small intestine, reducing
the carbohydrate amount of each meal and dividing the food intake
into at least five meals per day have been reported to be effective
(71). In addition, several other treatments, including surgery and
somatostatin administration, have been attempted to relieve late
dumping symptoms (74, 79, 80). Furthermore, α -GIs have been
demonstrated to inhibit carbohydrate digestion and cause delayed
glucose absorption and a diminished rise in blood glucose after
meals, thereby resulting in a reduction of postprandial hypergly-
cemia and insulin release. Therefore, α -GIs are considered effi-
cient in reducing the incidence of reactive hypoglycemia due to
late dumping syndrome (71, 81-90).
Case report
Case 8 : A 52-year-old man had undergone total gastrectomy
for gastric carcinoma at the age of 45 years. Since then, he had
occasionally experienced hypoglycemic symptoms such as sweat-
ing, fatigue, and disturbed consciousness after meal intake. CGMS
showed a rapid rise in postprandial glucose levels after a meal,
which declined shortly afterwards (Fig. 8a). The postprandial hyper-
glycemia was prominent, especially when he ingested carbohy-
drate-rich meals, such as curry with rice (Fig. 8a around 1 PM).
Acarbose (50 mg) administered just before each meal attenuated
his postprandial hyperglycemia, and his hypoglycemic symptoms
did not recur even after consuming the same lunch as the previous
day (curry with rice of the same portion at the same restaurant)
(Fig. 8b, around 1 PM). If he did not take acarbose before a meal,
his glucose levels started to rise immediately after dinner (Fig. 8c,
around 7 PM), suggesting that the drug was effective for attenu-
ating high postprandial glucose levels and preventing symptoms
associated with late dumping syndrome.
SUMMARY
Herein, we described the known pathophysiological back-
grounds of hyperglycemia associated with certain conditions ;
namely steroid use, liver cirrhosis, enteral nutrition, and reactive
hypoglycemia due to late dumping syndrome. We presented the
CGMS results of patients with these conditions, which showed
typical glycemic patterns for each condition, and observed the ef-
fects of various practical treatments. Based on these cases, we con-
clude that CGMS is a very useful investigative tool to determine
the glycemic patterns of the aforementioned conditions in a prac-
tical setting, and may be used to monitor the treatment success of
such cases.
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